Dr. Zaid on the evolving treatment paradigm for renal cell carcinoma
“Gone are the days when scalpel was king or queen in this space. The armamentarium of medications and systemic treatments, combination treatments has exploded, and our understanding of the biology of disease is expanding,” says Harras B. Zaid, MD.
In this video, Harras B. Zaid, MD, discusses treatment advances in the management of renal cell carcinoma (RCC), which was discusses during a session at SUO titled, “Panel Discussion: Salvage Therapies for Recurrence Following Local Therapy (Ablation, Systemic Therapy, XRT, Surgery).” Zaid is an assistant professor in the department of surgery and perioperative care at the University of Texas, Austin and a urologic oncologist at Dell Seton Medical Center.
Video Transcript:
One of the things that the panel discussion kept coming home to is that this is multidisciplinary approach. Gone are the days when scalpel was king or queen in this space. The armamentarium of medications–systemic treatments, combination treatments–has exploded, and our understanding of the biology of disease is expanding. Also non-surgical techniques–SBRT, thermal ablation techniques–have become more sophisticated. Before as surgeons we go in and operate in this disease space, we really need to think long and hard, engage our colleagues in medical and radiation oncology, and most importantly, have an honest discussion with our patients and their families, weighing the risks and benefits of upfront surgery versus upfront treatment. Patients and families will have priorities; financial toxicities and treatment fatigue need to be considered. I think all of these are now part of our care package of these patients.
This transcription has been edited for clarity.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.
